{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:11:32Z","timestamp":1788401492675,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","issue":"47","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.vaccine.2023.09.049","type":"journal-article","created":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T07:42:44Z","timestamp":1698133364000},"page":"6999-7006","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Consistency of immunogenicity in three consecutive lots of a tetravalent dengue vaccine candidate (TAK-003): A randomized placebo-controlled trial in US adults"],"prefix":"10.1016","volume":"41","author":[{"given":"Vianney","family":"Tricou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Winkle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie M.","family":"Tharenos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9908-8852","authenticated-orcid":false,"given":"Martina","family":"Rauscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Escudero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"LeFevre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Borkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.09.049_b0005","unstructured":"World Health Organization. Dengue guidelines for diagnosis, treatment, prevention and control: new edition. Geneva: WHO; 2009. Available at: https:\/\/apps.who.int\/iris\/handle\/10665\/44188. Accessed 19 September 2023."},{"key":"10.1016\/j.vaccine.2023.09.049_b0010","unstructured":"World Health Organization. Fact sheets. Dengue and severe dengue. Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dengue-and-severe-dengue. Accessed 19 September 2023."},{"issue":"1","key":"10.1016\/j.vaccine.2023.09.049_b0015","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1473-3099(01)00171-2","article-title":"Dengue: an update","volume":"2","author":"Guzman","year":"2002","journal-title":"Lancet Infect Dis"},{"issue":"9341","key":"10.1016\/j.vaccine.2023.09.049_b0020","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0140-6736(02)11276-1","article-title":"The future of dengue vaccines","volume":"360","author":"Halstead","year":"2002","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.vaccine.2023.09.049_b0025","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s00705-013-1645-3","article-title":"Secondary infection as a risk factor for dengue hemorrhagic fever\/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection","volume":"158","author":"Guzman","year":"2013","journal-title":"Arch Virol"},{"issue":"7","key":"10.1016\/j.vaccine.2023.09.049_b0030","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.imbio.2008.11.008","article-title":"Role of antibodies in controlling dengue virus infection","volume":"214","author":"van der Schaar","year":"2009","journal-title":"Immunobiology"},{"issue":"36","key":"10.1016\/j.vaccine.2023.09.049_b0035","first-page":"457","article-title":"WHO position paper \u2013 September 2018","volume":"93","year":"2018","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2023.09.049_b0040","series-title":"Arbovirus research in Australia: proceedings of the 4th symposium","first-page":"35","article-title":"Dengue virus vaccine development: study on biological markers of uncloned dengue 1\u20134 viruses serially passaged in primary kidney cells","author":"Yoksan","year":"1986"},{"issue":"27","key":"10.1016\/j.vaccine.2023.09.049_b0045","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1016\/j.vaccine.2018.05.028","article-title":"A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate","volume":"36","author":"Jackson","year":"2018","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2023.09.049_b0050","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1473-3099(17)30632-1","article-title":"Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2\u201317 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study","volume":"18","author":"S\u00e1ez-Llorens","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2023.09.049_b0055","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1080\/21645515.2020.1727697","article-title":"Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial","volume":"16","author":"Turner","year":"2020","journal-title":"Hum Vaccin Immunother"},{"issue":"10234","key":"10.1016\/j.vaccine.2023.09.049_b0060","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0140-6736(20)30556-0","article-title":"Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2\u201317 years: a randomised, placebo-controlled, phase 2 trial","volume":"395","author":"Tricou","year":"2020","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.vaccine.2023.09.049_b0065","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children and adolescents","volume":"381","author":"Biswal","year":"2019","journal-title":"N Engl J Med"},{"issue":"10234","key":"10.1016\/j.vaccine.2023.09.049_b0070","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(20)30414-1","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children aged 4\u201316 years: a randomised, placebo-controlled, phase 3 trial","volume":"395","author":"Biswal","year":"2020","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.vaccine.2023.09.049_b0075","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/infdis\/jiaa761","article-title":"Efficacy of a dengue vaccine candidate (TAK-003) in healthy children and adolescents two years after vaccination","volume":"225","author":"L\u00f3pez-Medina","year":"2022","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2023.09.049_b0080","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/cid\/ciab864","article-title":"Three years efficacy and safety of Takeda\u2019s dengue vaccine candidate (TAK-003)","volume":"75","author":"Rivera","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.09.049_b0085","series-title":"Presented at the 8th Northern European conference on travel medicine","article-title":"Efficacy and safety of Takeda\u2019s tetravalent dengue vaccine candidate (TAK-003) after 4.5 years of follow-up","author":"Tricou","year":"2023"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2023.09.049_b0090","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1542\/peds.2010-1722E","article-title":"Food and Drug Administration regulation and evaluation of vaccines","volume":"127","author":"Marshall","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2023.09.049_b0095","unstructured":"World Health Organization. Guidelines for plaque reduction neutralization testing of human antibodies to dengue viruses. Geneva: WHO; 2008. Available at: https:\/\/apps.who.int\/iris\/handle\/10665\/69687. Accessed 19 September 2023."},{"issue":"6","key":"10.1016\/j.vaccine.2023.09.049_b0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002952","article-title":"Variability in dengue titer estimates from plaque reduction neutralization tests poses a challenge to epidemiological studies and vaccine development","volume":"8","author":"Salje","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2023.09.049_b0105","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1080\/21645515.2015.1009819","article-title":"Phase III, randomized controlled trial in girls 9\u201315 years old to evaluate lot consistency of a novel nine-valent human papillomavirus L1 virus-like particle vaccine","volume":"11","author":"Luxembourg","year":"2015","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"10.1016\/j.vaccine.2023.09.049_b0110","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1001\/jama.2013.8042","article-title":"West Nile virus: review of the literature","volume":"310","author":"Petersen","year":"2013","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.vaccine.2023.09.049_b0115","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics10050302","article-title":"Serological diagnosis of flavivirus-associated human infections","volume":"10","author":"Musso","year":"2020","journal-title":"Diagnostics"},{"key":"10.1016\/j.vaccine.2023.09.049_b0120","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00334","article-title":"Cross-reactive immunity among flaviviruses","volume":"11","author":"Rathore","year":"2020","journal-title":"Front Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23011325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23011325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:30:41Z","timestamp":1759404641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23011325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":24,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0264410X23011325"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.09.049","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consistency of immunogenicity in three consecutive lots of a tetravalent dengue vaccine candidate (TAK-003): A randomized placebo-controlled trial in US adults","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.09.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Takeda Vaccines. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}